弓形虫表面抗原P35基因片段的表达纯化和抗原性分析

目的制备具有免疫活性的弓形虫表面抗原P35基因片段的重组蛋白,并对其抗原性进行分析。方法根据弓形虫RH株表面抗原P35的cDNA序列设计一对引物,利用PCR技术从RH株弓形虫基因组中扩增出P35的基因片段,将其克隆到T载体中,并通过基因测序加以证实;将其亚克隆至原核表达载体pET KDO中,在大肠杆菌中经IPTG诱导表达。采用免疫印迹法对表达产物进行抗原性分析。结果从弓形虫RH株基因组中成功扩增到P35目的基因,该基因在原核系统中经诱导表达出分子量约42 000 Da大小的融合蛋白,经免疫印迹实验表明,表达产物具有良好的抗原性,经亲和层析纯化后得到了重组蛋白。结论运用基因工程技术得到了高纯度并具有良好抗原性的弓形虫重组P35融合蛋白。     

Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38

The development of innovative technologies is steadily increasing the body of knowledge on molecules involved in physiological functions. Thus, several interleukins (ILs) have been identified and characterized in the past few years. Here, we detail the structural and functional characteristics of IL-34 to IL-38 with special attention to their involvement in inflammatory joint disease. IL-34 chiefly increases osteoclast activation and proliferation and therefore, it plays a direct role in bone destruction as seen in rheumatoid arthritis (RA). Regulatory T-cells (Tregs) express IL-35, which therefore exerts anti-inflammatory effects by restoring Treg suppressive capabilities and by inhibiting the Th17 pathway. IL-37 has anti-inflammatory effects mediated by a negative feedback loop that decreases the release of pro-inflammatory cytokines. IL-36 belongs to the IL-1 family and has three different forms. Although this cytokine has been chiefly studied in psoriasis and psoriatic arthritis, it also exerts pro-inflammatory effects in RA. The specific IL-36 antagonist, IL-36Ra binds to the IL-36 receptor, thereby, preventing signal transduction. Finally, IL-38 is a recently identified cytokine whose effect may resemble that of IL-36Ra as it binds to the IL-36 receptor and inhibits its effects, particularly the Th17-response. Although the exact roles for these cytokines awaits elucidation, the current improvements in our knowledge of the mechanisms that regulate chronic inflammatory conditions, such as RA may lead to the identification of new treatment targets.     

达因35联合小剂量地塞米松治疗多囊卵巢综合征的效果分析

目的：通过观察达因35联合小剂量地塞米松治疗多囊卵巢综合征（ PCOS）的临床效果,探讨PCOS高雄激素血症的有效治疗途径。方法将68名高雄激素血症性PCOS患者随机分为两组,分别给予口服达因35（达因组）和达因35联合小剂量地塞米松（地塞米松组）治疗3～6个周期,比较治疗前后PCOS患者多毛痤疮、肥胖指数、卵泡发育和排卵率以及血清激素的变化,并进行统计学分析。结果达因35和达因35联合小剂量地塞米松能够明显降低PCOS患者体内促黄体生成素（ LH）、游离睾酮（ FT）、雄烯二酮（ A）、硫酸脱氢表雄酮（DHEA－S）、17－羟孕酮（17－OHP）的水平,治疗3个周期地塞米松组显著低于达因组（P＜0.01）,治疗6个周期两组比较差异无显著性（ P＞0.05）;治疗3个周期达因35联合小剂量地塞米松可明显改善PCOS患者多毛、痤疮、卵泡发育和排卵率,与达因组比较差异有显著性（ P＜0.05）。结论小剂量地塞米松可协同达因35治疗PCOS高雄激素血症并明显缩短达因35的治疗周期,同时显著改善高雄激素血症引起的慢性无排卵、多毛痤疮等临床症状。     

二甲双胍与炔雌醇环丙孕酮片联用对多囊卵巢综合征患者相关激素分泌水平的影响

目的  观察并探讨二甲双胍（Met）与炔雌醇环丙孕酮片（达英-35）合用对多囊卵巢综合征（PCOS）患者相关激素分泌水平的影响。方法  选择2011年4月-2015年3月在该医院接受治疗的PCOS患者152例,按照随机数字法将152例患者分为观察组和对照组,每组76例。对照组月经后5d口服达英-35治疗,观察组在对照组基础上口服Met治疗。对两组治疗前后性激素水平[促黄体生成素（LH）、促卵泡激素（FSH）、睾丸素（TEST）]、稳态胰岛素评价指数（HOMA-IR）、胰岛素分泌指数（HOMA-β）进行比较,并评价综合疗效。结果  治疗前,两组LH、FSH、TEST、HOMA-IR和HOMA-β比较,差异无有统计学意义（P >0.05）;治疗后,观察组LH、FSH和TEST水平低于对照组（P <0.05）;治疗后,观察组HOMA-IR和HOMA-β低于对照组（P <0.05）;观察组总有效率为94.7%（72/76）,对照组为76.3%（58/76）,两组比较,差异有统计学意义（P <0.05）。结论  Met与达英-35联合治疗PCOS可以明显改善内分泌和胰岛素抵抗,疗效显著,是治疗PCOS的安全、有效方案。